pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›cadonilimab
drug · antibody
save

cadonilimab

Phase 2updated 3mo ago
by Akeso Inc🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 4
  • tagBreast Cancer7 co-mentions · 1 sources
  • tagOncology5 co-mentions · 1 sources
  • companyWuhan Union Hospital1 co-mentions · 1 sources
  • tagHER21 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 40 investigational indications.

targets

Programmed cell death protein 1Cytotoxic T-lymphocyte protein 4

all catalysts(1)

phase 2 completion · 1
Apr 30, 2026
phase 2 completion
4mo ago
Wuhan Union Hospital — cadonilimab (Phase II Trial Completion)
cadonilimab
→

Trials studying cadonilimab

  • phase2HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinomaactive not recruitingn=42
  • phase3Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinomanot yet recruitingn=900
  • phase2Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Canceractive not recruitingn=26
  • phase3Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancerrecruitingn=386
  • phase2AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Canceractive not recruitingn=110
  • phase2A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)recruitingn=280
  • EP1THIO and Cadonilimab in Resectable Hepatocellular Carcinomanot yet recruitingn=60
  • phase2Ligufalimab and Cadonilimab in Advanced Liver Cancersrecruitingn=64
more trials →

News(0)

no news has mentioned this drug yet

generic
cadonilimab
MOA
Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor
indication
Hepatocellular Carcinoma
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed just now
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?